^
Association details:
| Biomarker: | FAP expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | AAA614 (Ionizing radiation emitter, FAP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
571P - Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)
Published date:
09/14/2020
Excerpt:
Immunohistochemistry confirmed high levels of FAP expression, predominantly in CAFs, in multiple tumour types including pancreatic, breast, and sarcoma….FAP-2286 labelled with the therapeutic β-particle emitting radionuclide 177Lu, at a specific activity of 30 MBq/nmol (low-dose group) or 60 MBq/nmol (high-dose group), had potent anti-tumour activity in FAP expressing HEK-293 xenografts after a single IV dose: tumour growth inhibition at day 14 posttreatment was 112% and 115%, respectively, with no significant weight loss.
